In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells

BACKGROUND: Breast cancer treatment is based on a combination of adjuvant chemotherapy followed by radiotherapy effecting intracellular signal transduction. With the tyrosine kinase inhibitors new targeted drugs are available. Imatinib mesylate is a selective inhibitor of bcr-abl, PRGFR alpha, beta...

Descripción completa

Detalles Bibliográficos
Autores principales: Weigel, Marion T, Dahmke, Linda, Schem, Christian, Bauerschlag, Dirk O, Weber, Katrin, Niehoff, Peter, Bauer, Maret, Strauss, Alexander, Jonat, Walter, Maass, Nicolai, Mundhenke, Christoph
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925350/
https://www.ncbi.nlm.nih.gov/pubmed/20691121
http://dx.doi.org/10.1186/1471-2407-10-412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925350/
https://www.ncbi.nlm.nih.gov/pubmed/20691121
http://dx.doi.org/10.1186/1471-2407-10-412

Ejemplares similares